IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model - Wikidata - awgldk - TriplyDB

IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model

IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model

http://www.wikidata.org/entity/Q37125180

about

Immune-regulatory mechanisms in systemic autoimmune and rheumatic diseases Type I interferon blockade in systemic lupus erythematosus: where do we stand?TLRs and interferons: a central paradigm in autoimmunity Modelling clinical systemic lupus erythematosus: similarities, differences and success stories Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study.Distinct Functions of Autoantibodies Against Interferon in Systemic Lupus Erythematosus: A Comprehensive Analysis of Anticytokine Autoantibodies in Common Rheumatic Diseases A genomic approach to human autoimmune diseases.Lupus nephritis: lessons from murine models Activation of type I interferon pathway in systemic lupus erythematosus: association with distinct clinical phenotypes.Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis.Murine models of systemic lupus erythematosus The tolerogenic peptide, hCDR1, down-regulates the expression of interferon-α in murine and human systemic lupus erythematosus.Interferon-inducible gene 202b controls CD8(+) T cell-mediated suppression in anti-DNA Ig peptide-treated (NZB × NZW) F1 lupus mice.Amine-reactive OVA multimers for auto-vaccination against cytokines and other mediators: perspectives illustrated for GCP-2 in L. major infection.The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus IFN-α and CD46 stimulation are associated with active lupus and skew natural T regulatory cell differentiation to type 1 regulatory T (Tr1) cells Phenotypic and functional alterations of pDCs in lupus-prone mice.Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.IFNα Inducible Models of Murine SLE.IL-1 Vaccination Is Suitable for Treating Inflammatory Diseases.Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus.Plasmacytoid dendritic cells in antiviral immunity and autoimmunity.Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer.Immunodrugs: breaking B- but not T-cell tolerance with therapeutic anticytokine vaccines.Aberrant B-lymphocyte responses in lupus: inherent or induced and potential therapeutic targets.Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies.Type I IFNs as biomarkers in rheumatoid arthritis: towards disease profiling and personalized medicine.Targeting interferons in systemic lupus erythematosus: current and future prospects.Emerging therapies in systemic lupus erythematous: from clinical trial to the real life.Update on Biologic Therapies for Systemic Lupus Erythematosus.Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid.Humoral markers of active Epstein-Barr virus infection associate with anti-extractable nuclear antigen autoantibodies and plasma galectin-3 binding protein in systemic lupus erythematosus.JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation.[Auto-vaccines: an immunological alternative to gene silencing].[Update on the use of active anti-cytokine therapies with kinoid vaccines for the treatment of inflammatory diseases].Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer's and cat allergy.Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)/lpr mice.

P2860

Q26823714-377ADEDE-DB23-4D7B-8478-4183DB064B79 Q26865441-612C1EAB-A182-45E4-AECF-5660E3919AE7 Q27023982-5618EDBA-339C-4613-9817-9A7BCC518406 Q28074217-A86C2CC8-DC1F-4565-8995-601B9919C5B9 Q28265144-2EA09984-E0F4-4AED-A4E5-8725E5809C42 Q31111222-312B5E9E-D53C-4AA3-8E56-8ACAC21126A9 Q33563703-6DC8356C-A620-40BD-A107-B3A9AEE41293 Q33762839-FACAE512-842B-4D94-93E7-E3630D64E0DC Q33998360-2D21FE11-3CE5-46AC-B1DF-3D5D99EDAC0C Q34240254-76281AD7-931A-4B20-92C7-FE44DCE9ACD2 Q34413235-9DEB038E-9FB6-4C19-A249-C34D1546076F Q34591019-FB316900-DF44-4BAE-AA79-5E72445E1853 Q34653846-F1D96E08-92B4-42F5-8FDD-DCC1E6C65ECD Q35146773-57BE33AB-F269-4727-8CC2-60DFB9081ECB Q35168395-A4CBE2AF-684D-44A6-ACEF-25BE058F950D Q35294438-74FE6B54-F8D0-4045-A823-E9524EE7B588 Q35571367-AABFA2CF-0D19-412B-815B-5373F6659F49 Q36583115-ADDC1455-A008-4C0C-8E27-5AB69514E237 Q36844513-4A2E5802-E551-43F4-B070-EDA54293FE58 Q37210594-067E0695-6FB1-4F5B-B00B-5063960FBC1C Q37614491-1FAE1430-92CE-4595-856A-146541DECCF2 Q37730995-C30FA2B5-31B9-4EAE-B6B8-83F6256F39C5 Q37769441-C4D2EFA1-9C36-4830-A366-34653CF8AD6D Q37773243-7F82052D-1F76-488E-9540-F996B33EC799 Q37773295-749F05D6-0A6C-4F4B-917B-3BDBC487CB67 Q38108851-6A86C3EB-EBEB-4D22-9381-C7B201DF7170 Q38175493-EAF816CA-7DE9-412A-9E0C-6DD73D0DAF93 Q38335622-AB0C1BC9-945A-44FE-BB0B-066E9020C1B6 Q38458846-B94E954D-990E-4D8D-AA5B-F4858863A80A Q38747383-9189B9CB-1E33-4FCD-AD0B-F15CA163466D Q38864797-DBD90032-8759-495D-A90A-A63A968DEA40 Q40265943-B325CF92-F96B-4116-9E8B-081C90994A5C Q40473942-EBB3D2F3-0A03-441D-973A-B44B7DDCFCA1 Q41495831-09009E66-EE41-428D-A060-8CD938E6D73C Q43691412-94FD631B-90EB-41BE-8FF2-2CCE7619E16E Q45839762-740CBAD0-0E61-4CB2-8153-0BA749C9A691 Q47152622-E087688F-C82A-460B-B6C5-A8B7DDB05072 Q51036730-283F37D2-1229-4B6B-ACAC-157F97FA56B8

P2860

IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model

http://www.wikidata.org/entity/Q37125180

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

IFNalpha kinoid vaccine-induce ...... in a lupus flare murine model

@en

IFNalpha kinoid vaccine-induce ...... in a lupus flare murine model.

@nl

type

label

IFNalpha kinoid vaccine-induce ...... in a lupus flare murine model

@en

IFNalpha kinoid vaccine-induce ...... in a lupus flare murine model.

@nl

prefLabel

IFNalpha kinoid vaccine-induce ...... in a lupus flare murine model

@en

IFNalpha kinoid vaccine-induce ...... in a lupus flare murine model.

@nl

P1433

Q37125180-0B314E58-344C-42B1-84CE-9D369009F082

P1476

Q37125180-62AD36B7-8A7E-43C6-B249-B969A219F7BE

P2093

Q37125180-04266762-0260-4784-B65F-6F9EE0728A56

Q37125180-1FD6CC28-9069-4FEC-BF4F-E0910734E2CF

Q37125180-41668C4C-3F0E-4820-8AC5-5BA238BEB227

Q37125180-43C8065B-E61B-4CD6-9332-4AF833295C92

Q37125180-5B02F46B-A7CC-466D-B812-9F7812C43AB0

Q37125180-5E3EB90A-E33F-400C-872E-A61A6FD371ED

Q37125180-8D97E66F-5627-4E13-8382-8E23C1668581

Q37125180-AFE55AEF-B1DC-4461-B76D-C34E5AFC7227

Q37125180-E846B74C-BDD7-440B-9168-AD6893487361

P2860

Q37125180-00058184-7E15-4E96-8E15-9138085ED68B

Q37125180-176DAED4-069E-4780-8C2C-1B4244A2425A

Q37125180-2369319D-C973-420D-BCEC-D307868BA727

Q37125180-23948B00-1B18-4BE7-9DC4-5A32DF78A0DB

Q37125180-26DF7D35-8ABE-4B61-A3CA-51327015723D

Q37125180-28D56903-12EB-4B60-B4D2-A4B724701FFD

Q37125180-2B40DCD2-7C4C-41AE-99B7-4EBB00783FDD

Q37125180-2C2E5C13-EDD8-4ECA-BBCB-7A71754A1599

Q37125180-3D0FFC25-87AB-4DAB-9072-1A2C629974AE

Q37125180-46A872C1-8ED8-4EE5-86EF-DC96615AD078

P304

Q37125180-BC676E6E-7571-41CB-9398-2BC4ADE9F331

P31

Q37125180-0B8431B9-E3B7-48B3-9979-9DA8F1DE5A87

P356

Q37125180-480DA94F-672B-4F58-B493-0694EE6A1619

P407

Q37125180-0BFBECB4-8EA2-4FAC-96EE-74224FB73E57

P433

Q37125180-D867E86E-10A5-4406-B484-786508763ED3

P478

Q37125180-06E0BD0F-74E4-41C7-A049-03F60DEFC0BA

P50

Q37125180-37A182F1-7BC6-4C13-9676-7D7ACA9DE1BE

Q37125180-71709DFD-EA40-44FE-9CD0-DCE04314AF33

Q37125180-75755000-2033-405E-BC45-377CE4C71F4D

Q37125180-7E229FB8-65F9-4BA2-B7CE-FAF2B03D72F9

Q37125180-ECDB327F-28BD-4599-A172-15B8984658D2

P577

Q37125180-5854B47A-67E3-4F77-A705-158C3D6D4DC4

P5875

Q37125180-183A6AC8-5C0E-4A64-9704-8A6ABF9E8CCA

P698

Q37125180-7B1B5996-E89E-4F82-8D22-D8BD3C62CEFA

P921

Q37125180-E6AF9147-D91E-4A4E-9ED6-65D19D8AD3BF

P932

Q37125180-68F90617-AC3C-460E-A917-4EF59E05C79A

P356

PNAS.0900615106

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

IFNalpha kinoid vaccine-induce ...... in a lupus flare murine model

@en

P2093

Alexis Mathian

http://www.w3.org/2001/XMLSchema#string

Bernard Bizzini

http://www.w3.org/2001/XMLSchema#string

Daniel Zagury

http://www.w3.org/2001/XMLSchema#string

Dominique Emilie

http://www.w3.org/2001/XMLSchema#string

Gabriel Peltre

http://www.w3.org/2001/XMLSchema#string

Hélène Le Buanec

http://www.w3.org/2001/XMLSchema#string

Patrick Larcier

http://www.w3.org/2001/XMLSchema#string

Roger Burnett

http://www.w3.org/2001/XMLSchema#string

Sophie Koutouzov

http://www.w3.org/2001/XMLSchema#string

P2860

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy.

The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.

Cytokine fields and the polarization of the immune response.

Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases.

Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases.

TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation

VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases.

Anti-cytokine Ab immune therapy: present status and perspectives.

P304

5294-5299

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0900615106

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

Hélène Le Buanec

Armand Bensussan

P577

2009-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24194237

http://www.w3.org/2001/XMLSchema#string

P698

19279210

http://www.w3.org/2001/XMLSchema#string

P921

P932

2654395

http://www.w3.org/2001/XMLSchema#string